Introduction A collaboration of the CML Advocates Network / Leukaemia Patient Advocates Foundation with a major pharmaceutical company regarding the use of a medicine in Phase III trials (adult...
Patient engagement in medicines development: Recommendations on how to find the right match for the right patient engagement activity. Background/Rationale for the document During the analysis of existing practices...
Published and available for citation: Klingmann I, Heckenberg A, Warner K, Haerry D, Hunter A, May M and See W (2018) EUPATI and Patients in Medicines Research and Development:...
Transcription Hello, my name is Victoria Thomas and I’m the head of public involvement at organisation called the National Institute for Health and Care Excellence, also known as...
Before a medicinal product can be marketed and sold, a marketing authorisation must be obtained from the relevent National Competent Authorities. The marketing authorisation application process can take one...
Generic medicines are copies of original, branded medicines. They can be manufactured and sold after the protection on an original product expires. They have the same form and active...
Transcript My name is Matthew May. I work for DIA, which is a non-profit in the pharmaceutical industry. We’re a global membership association who also provide conferences and...
Transcription I’m Gilli Spurrier-Bernard. I am a patient advocate because my husband is a stage 4 melanoma patient. As a patient advocate I initiated the Melanome France group...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy
